NERV vs ALTO vs ACAD vs REX vs INVA

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -4. 9% for Alto Ingredients, Inc. (ALTO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (6. 4x forward), making it the more compelling value choice. Analysts rate Minerva Neurosciences, Inc. (NERV) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Alto Ingredients, Inc. at 35. 6x. On forward P/E, Innoviva, Inc. is actually cheaper at 6. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 0. 62x versus REX American Resources Corporation's 0. 75x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, REX American Resources Corporation (REX) delivered a total return of +171.

6%, compared to -81. 0% for Minerva Neurosciences, Inc. (NERV). Over 10 years, the gap is even starker: REX returned +347. 0% versus NERV's -94. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 06β versus Minerva Neurosciences, Inc. 's 1. 28β — meaning NERV is approximately 2134% more volatile than INVA relative to the S&P 500. On balance sheet safety, REX American Resources Corporation (REX) carries a lower debt/equity ratio of 3% versus 40% for Alto Ingredients, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus -4. 9% for Alto Ingredients, Inc. (ALTO). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -183. 5% for Minerva Neurosciences, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus 0. 0% for Minerva Neurosciences, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 0. 0% for NERV. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 0. 62x versus REX American Resources Corporation's 0. 75x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Innoviva, Inc. (INVA) trades at 6. 4x forward P/E versus 56. 7x for REX American Resources Corporation — 50. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 75. 9% to $40. 00.

In this comparison, ALTO (0.

3% yield) pays a dividend. NERV, ACAD, REX, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, REX American Resources Corporation (REX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

22), +347. 0% 10Y return). Both have compounded well over 10 years (REX: +347. 0%, NERV: -94. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NERV (Healthcare) and ALTO (Basic Materials) and ACAD (Healthcare) and REX (Basic Materials) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NERV is a small-cap quality compounder stock; ALTO is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; REX is a small-cap deep-value stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.